.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL06_OlodaterolAndTiotropiumB.OlodaterolAndTiotropiumB

Information

Olodaterol and tiotropium bromide is a fixed-dose combination inhalation therapy used as a long-acting bronchodilator for maintenance treatment of chronic obstructive pulmonary disease (COPD). Olodaterol is a long-acting beta2-adrenergic agonist (LABA), and tiotropium bromide is a long-acting muscarinic antagonist (LAMA). The combination is approved and widely prescribed for adults with COPD to improve lung function and reduce symptoms.

Pharmacokinetics

Pharmacokinetic parameters based on published healthy adult and COPD subject studies with fixed-dose inhalation of olodaterol/tiotropium bromide combination (equivalent to 5 mcg olodaterol and 5 mcg tiotropium bromide daily).

References

1. Wang, Z, et al., & Luo, Z (2020). Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD. Pulmonary pharmacology & therapeutics 63 101944–None. DOI:10.1016/j.pupt.2020.101944 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32916296

2. Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75(6) 665–673. DOI:10.1007/s40265-015-0371-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773742

Revisions

• 06/2025 initial generated model